Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Austrade virtual China conference with AstraZeneca, Wuxi iCampus and CSIRO, July 2020
13 slides from Optiscan Imaging's conference presentation, Jul 24, 2020
Slide 1: Optiscan Presentation
ASX Announcement 24 July 2020 Optiscan Presentation Optiscan Imaging Ltd (“Optiscan” or “Company”) is participating in a virtual conference from 20 to 24 July 2020 delivered by Austrade in partnership with biopharmaceutical giant AstraZeneca, Wuxi iCampus and CSIRO, designed to equip founders with t
Slide 2: Optiscan Imaging Ltd (ASX:OIL)
Optiscan Imaging Ltd (ASX:OIL) Enabling “Real-time Virtual Biopsy” for Human Cancer Screening and Surgical Margin Detection
Slide 3: Notice
Notice This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 24 July 2020. The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor may r
Slide 4: Notice
Notice Not an offer or financial productadvice This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This presentation does not satisfy the disclosure requirements for a disclosure docu
Slide 5: OPTISCAN Introduction - Technology
OPTISCAN Introduction - Technology ❑ Hand-held Confocal Endomicroscope for Medical 4.7 mm Diameter Tip and Research Imaging ❑ World-leading and Patent Protected ❑ Real-time “Virtual Biopsy“ ❑ Reduced and More Targeted Biopsies ❑ Capture all Cancer Cells and reduce Tumour Margin in Surgery Optiscan P
Slide 6: Optiscan Applications and Devices
Optiscan Applications and Devices Clinical Applications and Devices: ❑ Oral Cancer - InVivage® ❑ Breast Cancer - InVivage® ❑ Neurosurgery – CONVIVO® (Carl Zeiss Meditec Co-operation) Pre-clinical Device: FIVE2 (ViewVivo®) ❑ Laboratory & Translational Experiments ❑ Medical Research Facilities and Uni
Slide 7: Oral Cancer Diagnosis, Survival Rates and Economic Cost
Oral Cancer Diagnosis, Survival Rates and Economic Cost >80% 57% 2.5x Survival Survival Cost 80-90% Five Year 57% Five Year 2.5x More Survival Rate in Survival Rate in Economic Burden Early Diagnosis1 Late Diagnosis1 when Diagnosed Late2 1. Oral Cancer Foundation. https://oralcancerfoundation.org/ 2
Slide 8: Oral Market Size - China
Oral Market Size - China ❑China: 48 Public Tertiary Dental Hospitals ❑Guangdong Province: 158 Stomatology Departments in General Hospitals, 14 Public and Private Dental Hospitals Leading Specialist Dental Hospitals: Name Location No. of Chairs Patient Volume (Out patient annually) KPMG. (2016). Comm
Slide 9: OPTISCAN – Oral Cancer Progress
OPTISCAN – Oral Cancer Progress 3 Oral Cancer Studies and Trials ❑ Received Federal Government ~ A$1million (~¥5million) grant for 150 patient Oral Cancer Study at Melbourne Dental School ❑ Trial on-going at the Memorial Sloan Kettering Cancer Centre in New York ❑ Trial on-going at the Australian Ce
Slide 10: Breast Cancer - Most Common Cancer in Women
Breast Cancer - Most Common Cancer in Women 2.1 8.5% 2.5 Million Million 2.1 million new breast 8.5% of all new cancer In 2021, total breast cancer cases predicted cases in China are breast cancer patients in China globally in 20181 cancer 2 will be 2.5 million 3 ❑ Rate of breast cancer in China is
Slide 11: CONVIVO® – Carl Zeiss Meditech (CZM) Co-operation
CONVIVO® – Carl Zeiss Meditech (CZM) Co-operation 297K Brain and CNS cancer cases every year worldwide ❑ Tumour margin detection in Brain Cancer surgery ❑ FDA 510(k) Clearance and CE Mark obtained
Slide 12: Distributor Strategy for China Pre-Clinical Market
Distributor Strategy for China Pre-Clinical Market New multi-distributor model in China with appointment of exclusive distributor in Southern and Western China. ❑ South and West China: Guangzhou Yunxing (Purple and Blue) ❑ East China: Biotimes Technology Limited (Green)
Slide 13: China Engagement Opportunities
China Engagement Opportunities ❑ Optiscan is looking to expand both its clinical and pre-clinical activities in China. ❑ Seeking partners for clinical trial activity, industry collaboration, distribution and growth initiatives.